Microbiology · Year 2 · from Microbiology
Case 2: Latent Tuberculosis Before Immunosuppressive Therapy
Presentation
A 45-year-old woman with rheumatoid arthritis is being considered for adalimumab (a TNF-alpha inhibitor) therapy due to inadequate response to methotrexate. As part of pre-treatment screening, an interferon-gamma release assay (IGRA) is ordered and returns positive. She reports no symptoms of cough, fever, night sweats, or weight loss. Her chest radiograph is normal. She has no known TB exposure history but immigrated from the Philippines 15 years ago.
Clinical Image
Histopathologic section showing a granuloma with central caseous necrosis surrounded by epithelioid histiocytes, giant cells, and a lymphocyte mantle - the characteristic tissue response to M. tuberculosis.
Image Source: Lecture image - tuberculosis pathology
Questions
- What is the diagnosis, and how does it differ from active tuberculosis?
- Why is treatment of this condition particularly important before TNF-alpha inhibitor therapy?
- What are the current preferred treatment regimens for this condition?
- What monitoring is required during treatment?
Answers
- Diagnosis: The diagnosis is latent tuberculosis infection (LTBI). LTBI is defined as immunologic evidence of prior TB exposure (positive TST or IGRA) without clinical, radiographic, or microbiologic evidence of active disease. The patient is asymptomatic, has a normal chest X-ray, and would have negative respiratory cultures. Unlike active TB, patients with LTBI are not infectious and do not require isolation. However, LTBI represents dormant organisms that can reactivate.
- Importance before TNF-alpha inhibitor therapy: TNF-alpha is essential for granuloma formation and maintenance. Granulomas contain M. tuberculosis infection by walling off the organisms with immune cells. TNF-alpha inhibitors disrupt this immune containment, dramatically increasing the risk of LTBI reactivation to active disease - typically 4-10 fold higher than untreated individuals. Without LTBI treatment, patients on TNF inhibitors may develop severe, often disseminated or extrapulmonary tuberculosis.
- Preferred treatment regimens for LTBI:
- 3HP regimen (preferred): Weekly isoniazid plus rifapentine for 12 doses (3 months) - highest completion rates
- 4R regimen: Daily rifampin for 4 months - isoniazid-sparing option
- 6H or 9H regimen: Daily isoniazid for 6 or 9 months - longer duration, lower completion rates
Treatment should ideally be initiated 1-2 months before starting TNF inhibitor therapy, though if the clinical situation is urgent, both can be started together. LTBI treatment should continue even after starting immunosuppression.
- Monitoring during treatment:
- Hepatotoxicity monitoring: Baseline LFTs, then monthly symptom assessment; routine LFT monitoring recommended for patients with baseline liver disease, HIV, pregnancy, or concurrent hepatotoxic medications
- Clinical assessment: Monthly evaluation for symptoms of hepatitis (nausea, anorexia, abdominal pain, dark urine, jaundice)
- Symptoms of active TB: Any development of cough, fever, weight loss, or night sweats requires evaluation to rule out active disease
Drug should be discontinued if ALT exceeds 3x upper limit of normal with symptoms or 5x upper limit without symptoms.